Jenny Garkaby, O. Scott, Laura Abrego Fuentes, L. Vong, Jessica Willett-Pachul, Myra Pereira, V. Kim, C. Roifman
{"title":"先天性免疫缺陷成年患者COVID-19结局的病例系列研究","authors":"Jenny Garkaby, O. Scott, Laura Abrego Fuentes, L. Vong, Jessica Willett-Pachul, Myra Pereira, V. Kim, C. Roifman","doi":"10.14785/lymphosign-2022-0009","DOIUrl":null,"url":null,"abstract":"Background: Since the onset of the COVID-19 pandemic, a main challenge for clinicians and public health decision-makers has revolved around risk stratification in vulnerable populations, in particular individuals with inborn errors of immunity (IEI). However, available reports of the clinical course of COVID-19 in patients with IEI show wide variability, from a complete lack of symptoms to severe and complicated disease. Objective: To present the clinical features and outcomes of SARS-CoV-2 infection in adult patients with IEI. Methods: A retrospective chart review involving patient characteristics and clinical course of SARS-CoV-2 infection between December 2021-July 2022. Results: Ten adult patients with IEI followed in our center were diagnosed with COVID-19, as determined by RT-PCR or rapid antigen test. IEI in this cohort included both humoral, combined immunodeficiencies and phagocytic defects, with an underlying lung comorbidity identified in 3 patients. Symptoms were mostly mild and self-limiting. No severe outcomes, complications or mortality were noted in this study. Conclusions: We suggest that patients affected by a wide range of both humoral and combined IEI may demonstrate resilience, while highlighting the possible protective effects of vaccination and immunoglobulin replacement in this population.","PeriodicalId":53881,"journal":{"name":"LymphoSign Journal-The Journal of Inherited Immune Disorders","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case series of COVID-19 outcomes in adult patients with inborn errors of immunity\",\"authors\":\"Jenny Garkaby, O. Scott, Laura Abrego Fuentes, L. Vong, Jessica Willett-Pachul, Myra Pereira, V. Kim, C. Roifman\",\"doi\":\"10.14785/lymphosign-2022-0009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Since the onset of the COVID-19 pandemic, a main challenge for clinicians and public health decision-makers has revolved around risk stratification in vulnerable populations, in particular individuals with inborn errors of immunity (IEI). However, available reports of the clinical course of COVID-19 in patients with IEI show wide variability, from a complete lack of symptoms to severe and complicated disease. Objective: To present the clinical features and outcomes of SARS-CoV-2 infection in adult patients with IEI. Methods: A retrospective chart review involving patient characteristics and clinical course of SARS-CoV-2 infection between December 2021-July 2022. Results: Ten adult patients with IEI followed in our center were diagnosed with COVID-19, as determined by RT-PCR or rapid antigen test. IEI in this cohort included both humoral, combined immunodeficiencies and phagocytic defects, with an underlying lung comorbidity identified in 3 patients. Symptoms were mostly mild and self-limiting. No severe outcomes, complications or mortality were noted in this study. Conclusions: We suggest that patients affected by a wide range of both humoral and combined IEI may demonstrate resilience, while highlighting the possible protective effects of vaccination and immunoglobulin replacement in this population.\",\"PeriodicalId\":53881,\"journal\":{\"name\":\"LymphoSign Journal-The Journal of Inherited Immune Disorders\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"LymphoSign Journal-The Journal of Inherited Immune Disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14785/lymphosign-2022-0009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"LymphoSign Journal-The Journal of Inherited Immune Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14785/lymphosign-2022-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Case series of COVID-19 outcomes in adult patients with inborn errors of immunity
Background: Since the onset of the COVID-19 pandemic, a main challenge for clinicians and public health decision-makers has revolved around risk stratification in vulnerable populations, in particular individuals with inborn errors of immunity (IEI). However, available reports of the clinical course of COVID-19 in patients with IEI show wide variability, from a complete lack of symptoms to severe and complicated disease. Objective: To present the clinical features and outcomes of SARS-CoV-2 infection in adult patients with IEI. Methods: A retrospective chart review involving patient characteristics and clinical course of SARS-CoV-2 infection between December 2021-July 2022. Results: Ten adult patients with IEI followed in our center were diagnosed with COVID-19, as determined by RT-PCR or rapid antigen test. IEI in this cohort included both humoral, combined immunodeficiencies and phagocytic defects, with an underlying lung comorbidity identified in 3 patients. Symptoms were mostly mild and self-limiting. No severe outcomes, complications or mortality were noted in this study. Conclusions: We suggest that patients affected by a wide range of both humoral and combined IEI may demonstrate resilience, while highlighting the possible protective effects of vaccination and immunoglobulin replacement in this population.